These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 17465195

  • 1. Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells.
    Yoshida M, Matsui Y, Ikarashi Y, Usui T, Osada H, Wakasugi H.
    Anticancer Res; 2007; 27(2):729-36. PubMed ID: 17465195
    [Abstract] [Full Text] [Related]

  • 2. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N.
    Cancer Res; 1989 Aug 01; 49(15):4098-102. PubMed ID: 2472873
    [Abstract] [Full Text] [Related]

  • 3. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells.
    Honore S, Kamath K, Braguer D, Horwitz SB, Wilson L, Briand C, Jordan MA.
    Cancer Res; 2004 Jul 15; 64(14):4957-64. PubMed ID: 15256469
    [Abstract] [Full Text] [Related]

  • 4. Apoptosis induction via microtubule disassembly by an antitumour compound, pironetin.
    Kondoh M, Usui T, Nishikiori T, Mayumi T, Osada H.
    Biochem J; 1999 Jun 01; 340 ( Pt 2)(Pt 2):411-6. PubMed ID: 10333483
    [Abstract] [Full Text] [Related]

  • 5. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression.
    Wehbe H, Kearney CM, Pinney KG.
    Anticancer Res; 2005 Jun 01; 25(6B):3865-70. PubMed ID: 16309172
    [Abstract] [Full Text] [Related]

  • 6. Gene expression and mitotic exit induced by microtubule-stabilizing drugs.
    Chen JG, Yang CP, Cammer M, Horwitz SB.
    Cancer Res; 2003 Nov 15; 63(22):7891-9. PubMed ID: 14633718
    [Abstract] [Full Text] [Related]

  • 7. Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.
    Locke V, Davey R, Davey M.
    Cytometry; 2001 Mar 01; 43(3):170-4. PubMed ID: 11170102
    [Abstract] [Full Text] [Related]

  • 8. Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines.
    Whang YM, Park KH, Jung HY, Jo UH, Kim YH.
    Cancer; 2009 Mar 15; 115(6):1253-66. PubMed ID: 19156899
    [Abstract] [Full Text] [Related]

  • 9. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
    Zhou J, O'brate A, Zelnak A, Giannakakou P.
    Cancer Res; 2004 Dec 01; 64(23):8708-14. PubMed ID: 15574781
    [Abstract] [Full Text] [Related]

  • 10. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.
    Gan PP, Pasquier E, Kavallaris M.
    Cancer Res; 2007 Oct 01; 67(19):9356-63. PubMed ID: 17909044
    [Abstract] [Full Text] [Related]

  • 11. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
    Yang C, Hornicek FJ, Wood KB, Schwab JH, Mankin H, Duan Z.
    Cancer Chemother Pharmacol; 2009 Aug 01; 64(3):607-14. PubMed ID: 19125251
    [Abstract] [Full Text] [Related]

  • 12. Cellular models of drug- and radiation-resistant small cell lung cancer.
    Davey RA, Locke VL, Henness S, Harvie RM, Davey MW.
    Anticancer Res; 2004 Aug 01; 24(2A):465-71. PubMed ID: 15152945
    [Abstract] [Full Text] [Related]

  • 13. The anticancer natural product pironetin selectively targets Lys352 of alpha-tubulin.
    Usui T, Watanabe H, Nakayama H, Tada Y, Kanoh N, Kondoh M, Asao T, Takio K, Watanabe H, Nishikawa K, Kitahara T, Osada H.
    Chem Biol; 2004 Jun 01; 11(6):799-806. PubMed ID: 15217613
    [Abstract] [Full Text] [Related]

  • 14. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK, Davey MW, Davey RA.
    Cancer Chemother Pharmacol; 2006 Aug 01; 58(2):256-65. PubMed ID: 16283310
    [Abstract] [Full Text] [Related]

  • 15. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
    Gan PP, Kavallaris M.
    Cancer Res; 2008 Dec 01; 68(23):9817-24. PubMed ID: 19047161
    [Abstract] [Full Text] [Related]

  • 16. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.
    Coley HM, Twentyman PR, Workman P.
    Anticancer Drug Des; 1992 Dec 01; 7(6):471-81. PubMed ID: 1337431
    [Abstract] [Full Text] [Related]

  • 17. Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells.
    Sadava D, Ahn J, Zhan M, Pang ML, Ding J, Kane SE.
    Cancer Chemother Pharmacol; 2002 Apr 01; 49(4):261-6. PubMed ID: 11914903
    [Abstract] [Full Text] [Related]

  • 18. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole.
    Chu SW, Badar S, Morris DL, Pourgholami MH.
    Anticancer Res; 2009 Oct 01; 29(10):3791-6. PubMed ID: 19846910
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells.
    AbouEl Hassan MA, Braam SR, Kruyt FA.
    Cancer Gene Ther; 2006 Dec 01; 13(12):1105-14. PubMed ID: 16841078
    [Abstract] [Full Text] [Related]

  • 20. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.
    Chen JG, Horwitz SB.
    Cancer Res; 2002 Apr 01; 62(7):1935-8. PubMed ID: 11929805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.